


## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **exenatide** (GLP-1 Receptor Agonists)
- Comparator (class): **dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Bladder cancer**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	36,976	20,736	14	0.68
Merative CCAE	3,060	1,726	<5	<2.90
Merative MDCCD	534	276	0	0.00
Merative MDCR	186	88	0	0.00
Optum Clinformatics	1,383	891	0	0.00
Optum EHR	2,993	1,249	0	0.00
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

